| Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer I Dufait, JK Schwarze, T Liechtenstein, W Leonard, H Jiang, D Escors, ... Oncotarget 6 (14), 12369, 2015 | 72 | 2015 |
| Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species H Wang, S Bouzakoura, S De Mey, H Jiang, K Law, I Dufait, C Corbet, ... Oncotarget 8 (22), 35728, 2017 | 62 | 2017 |
| PD-L1/PD-1 co-stimulation, a brake for T cell activation and a T cell differentiation signal T Liechtenstein, I Dufait, C Bricogne, A Lanna, J Pen, K Breckpot, ... Journal of clinical & cellular immunology, 2012 | 61 | 2012 |
| Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy T Liechtenstein, I Dufait, A Lanna, K Breckpot, D Escors Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly …, 2012 | 59 | 2012 |
| Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of … T Liechtenstein, N Perez-Janices, I Blanco-Luquin, C Goyvaerts, ... Oncoimmunology 3 (7), e945378, 2014 | 49 | 2014 |
| Retroviral and lentiviral vectors for the induction of immunological tolerance I Dufait, T Liechtenstein, A Lanna, C Bricogne, R Laranga, A Padella, ... Scientifica 2012, 2012 | 47 | 2012 |
| Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy I Dufait, E Van Valckenborgh, E Menu, D Escors, M De Ridder, K Breckpot Oncotarget 7 (27), 42698, 2016 | 40 | 2016 |
| Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells? D Escors, T Liechtenstein, N Perez-Janices, J Schwarze, I Dufait, ... Oncoimmunology 2 (10), e26148, 2013 | 35 | 2013 |
| Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion W Leonard, I Dufait, JK Schwarze, K Law, B Engels, H Jiang, ... Radiotherapy and Oncology 119 (2), 291-299, 2016 | 29 | 2016 |
| Antidiabetic biguanides radiosensitize hypoxic colorectal cancer cells through a decrease in oxygen consumption S De Mey, H Jiang, C Corbet, H Wang, I Dufait, K Law, E Bastien, ... Frontiers in pharmacology 9, 1073, 2018 | 28 | 2018 |
| Immune modulation by genetic modification of dendritic cells with lentiviral vectors T Liechtenstein, N Perez-Janices, C Bricogne, A Lanna, I Dufait, ... Virus research 176 (1-2), 1-15, 2013 | 28 | 2013 |
| Perforin and granzyme B expressed by murine myeloid-derived suppressor cells: a study on their role in outgrowth of cancer cells I Dufait, J Pardo, D Escors, Y De Vlaeminck, H Jiang, M Keyaerts, ... Cancers 11 (6), 808, 2019 | 22 | 2019 |
| Dichloroacetate radiosensitizes hypoxic breast cancer cells S de Mey, I Dufait, H Jiang, C Corbet, H Wang, M Van De Gucht, ... International Journal of Molecular Sciences 21 (24), 9367, 2020 | 16 | 2020 |
| Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose … JK Schwarze, G Awada, L Cras, J Tijtgat, R Forsyth, I Dufait, S Tuyaerts, ... Vaccines 8 (4), 670, 2020 | 16 | 2020 |
| Lentiviral vectors in immunotherapy I Dufait, T Liechtenstein, A Lanna, R Laranga, A Padella, C Bricogne, ... Gene Therapy-Tools and Potential Applications, 2013 | 9 | 2013 |
| Radioresistance of human cancers: clinical implications of genetic expression signatures S de Mey, I Dufait, M De Ridder Frontiers in Oncology, 4457, 2021 | 8 | 2021 |
| Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells P Kalus, J De Munck, S Vanbellingen, L Carreer, T Laeremans, K Broos, ... International Journal of Molecular Sciences 23 (9), 4865, 2022 | 6 | 2022 |
| Unraveling the effects of a talimogene laherparepvec (T-VEC)-induced tumor oncolysate on myeloid dendritic cells J Tijtgat, J De Munck, I Dufait, JK Schwarze, I Van Riet, L Franceschini, ... Frontiers in Immunology 12, 733506, 2021 | 6 | 2021 |
| A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma. JK Schwarze, J Duerinck, I Dufait, G Awada, S Klein, L Fischbuch, ... Journal of Clinical Oncology 38 (15_suppl), 2534-2534, 2020 | 6 | 2020 |
| Potential of memory T cells in bridging preoperative chemoradiation and immunotherapy in rectal cancer S de Mey, H Jiang, H Wang, B Engels, T Gevaert, I Dufait, O Feron, J Aerts, ... Radiotherapy and Oncology 127 (3), 361-369, 2018 | 5 | 2018 |
David Escors Murugarren (ORCID:000...Principal Investigator, NavarraBiomed, University College LondonBestätigte E-Mail-Adresse bei ucl.ac.uk
